eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Ulivi, Paola ^a   Scarpi, Emanuela ^a   Passardi, Alessandro ^a   Marisi, Giorgia ^a   Calistri, Daniele ^a   Zoli, Wainer ^a   Del Re, Marzia ^b   Frassineti, Giovanni Luca ^a   Tassinari, Davide ^c   Tamberi, Stefano ^d   Vertogen, Bernadette ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Ospedale Per Gli Infermi   (Italy)

^d Degli Infermi Hospital   (Italy)

Author keywords

Advanced colorectal cancer; Bevacizumab; eNOS; SNPs; VEGF

Indexed keywords

BEVACIZUMAB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; NOS3 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; ENOS GENE; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; VEGF GENE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETICS; METASTASIS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BEVACIZUMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938770819     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0619-5     Document Type: Article

References (34)

1. Banerjee S, Flores-Rozas H (2010) Monoclonal antibodies for targeted therapy in colorectal cancer. Cancer Biol Ther 9:563-571
2. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995
3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1407-1408
4. Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP et al (2015) Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer 112:963-970
5. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O (2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14:22-28
6. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443-448
7. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232-1235
8. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML et al (2011) Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 26:143-151
9. Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I et al (2012) Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 12:468-475
10. Morita S, Uehara K, Nakayama G, Shibata T, Oguri T, Inada-Inoue M et al (2013) Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 71:405-411
11. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P et al (2011) Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 11:247
12. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T et al (2013) Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One 8:e66774
13. Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A (2013) Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 30:327
14. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H et al (2012) Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 92:503-510
15. Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A et al (2015) Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 26:1201-1207
16. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
17. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 57:289-300
18. Marisi G, Passardi A, Calistri D, Zoli W, Amadori D, Ulivi P (2014) Discrepancies between VEGF -1154G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue. Int J Mol Sci 15:13333-13343
19. Gibbons GH, Dzau VJ (1994) The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438
20. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF (1998) Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 97:2494-2498
21. Winnik S, Lohmann C, Siciliani G, von Lukowicz T, Kuschnerus K, Kraenkel N et al (2013) Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis-implications for cardiovascular safety. Int J Cardiol 168:2453-2461
22. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54:652-658
23. Yang B, Xu JR, Liu XM, Yang Y, Na XF, Li M et al (2013) Polymorphisms of rs1799983 (G > T) and rs1800780 (A > G) of the eNOS gene associated with susceptibility to essential hypertension in the Chinese Hui ethnic population. Genet Mol Res 12:3821-3829
24. Wang J, Dudley D, Wang XL (2002) Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 22:e1-e4
25. Senthil D, Raveendran M, Shen YH, Utama B, Dudley D, Wang J et al (2005) Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells. DNA Cell Biol 24:218-224
26. Zhang MX, Ou H, Shen YH, Wang J, Wang J, Coselli J et al (2005) Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci USA 102:16967-16972
27. Ou H, Shen YH, Utama B, Wang J, Wang X, Coselli J et al (2005) Effect of nuclear actin on endothelial nitric oxide synthase expression. Arterioscler Thromb Vasc Biol 25:2509-2514
28. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A et al (1998) Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 245:190-193
29. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J (2000) Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 471:45-50
30. Yoon Y, Song J, Hong SH, Kim JQ (2000) Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem 46:1626-1630
31. Jachymova M, Horky K, Bultas J, Kozich V, Jindra A, Peleska J et al (2001) Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 284:426-430
32. Hingorani AD (2003) Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 5:19-25
33. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J (2000) Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97:2832-2835
34. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT et al (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13:724-733